|
||
Home | About | Contact | Vitamins for Schizophrenia |
|
April 07, 2006Theragenetics for Schizophrenia DiagnosticsRead more... Schizophrenia Diagnosis
IP2IPO Group PLC, the intellectual property commercialisation company, said it has invested 390,000 stg for a 48 pct stake in Theragenetics Ltd, a pharmacogenetic diagnostics spin-out company from the Institute of Psychiatry, King's College London (UK). Theragenetics said it will develop and commercialise pharmacogenetic diagnostic tests to help guide and improve the treatment of schizophrenia and other disorders Commenting on today's announcement, Alan Aubrey, IP2IPO's Chief Executive, said: 'We believe that the high reputation enjoyed by the Institute of Psychiatry at King's is well justified and are very pleased to be establishing what will be our first spin-out company from the School. Theragenetics is addressing a large and important market and we consider that it has the potential to make a Alison Campbell, Managing Director of King's College London Enterprises, said: For more information: CommentsPost a comment |
|